Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · IEX Real-Time Price · USD
7.33
-0.23 (-3.04%)
At close: Jul 19, 2024, 4:00 PM
7.32
-0.01 (-0.14%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Acrivon Therapeutics Employees
As of December 31, 2023, Acrivon Therapeutics had 61 total employees, including 58 full-time and 3 part-time employees. The number of employees increased by 17 or 38.64% compared to the previous year.
Employees
61
Change (1Y)
17
Growth (1Y)
38.64%
Revenue / Employee
n/a
Profits / Employee
-$1,051,115
Market Cap
226.33M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 61 | 17 | 38.64% |
| Dec 31, 2022 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inogen | 834 |
| 23andMe Holding Co. | 582 |
| 2seventy bio | 274 |
| Butterfly Network | 225 |
| NeuroPace | 171 |
| Molecular Partners AG | 168 |
| ESSA Pharma | 50 |
| Zura Bio | 15 |
ACRV News
- 7 weeks ago - Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data - Market Watch
- 3 months ago - Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event - GlobeNewsWire
- 3 months ago - Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 - GlobeNewsWire
- 3 months ago - Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan - GlobeNewsWire
- 3 months ago - Acrivon Therapeutics Announces $130 Million Private Placement Financing - GlobeNewsWire
- 4 months ago - Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights - GlobeNewsWire